Drug updated on 12/11/2024
| Dosage Form | Inhalation: budesonide (160 mcg), glycopyrrolate (9 mcg), formoterol fumarate (4.8 mcg) per inhalation |
| Drug Class | Inhaled corticosteroids (ICS), anticholinergics and long-acting beta2-adrenergic agonists (LABA) |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD)
Latest News
Summary
- This summary is based on the review of eight systematic review/meta-analysis. [1]
- Lung Function and Exacerbation Reduction: Budesonide/Glycopyrrolate/Formoterol Fumarate (BGF) demonstrated improved lung function and reduced moderate (4.01) and severe (0.87) exacerbations over a lifetime horizon in patients with moderate to very severe Chronic Obstructive Pulmonary Disease (COPD), compared to long-acting muscarinic antagonist/long-acting beta2-agonist (LAMA/LABA) therapies, which reported 8.42 and 2.04 exacerbations, respectively.
- Cost-effectiveness in Chinese Healthcare Context: BGF was found to be cost-effective in treating moderate to very severe COPD, with an incremental cost-effectiveness ratio (ICER) of CN$13,685.94 (US$1983.47) per quality-adjusted life year (QALY) gained, remaining below the cost-effectiveness threshold of CN$72,447.00 (US$10,499.57) in scenario and sensitivity analyses.
- There is no safety information available in the reviewed studies.
- There is no population types or subgroups information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Breztri Aerosphere (budesonide, glycopyrrolate, formoterol fumarate) Prescribing Information. | 2020 | AstraZeneca Pharmaceuticals LP, Wilmington, DE |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model | 2022 | Applied Health Economics And Health Policy |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Updates from 2023 guidelines: part 2. | 2024 | Canadian Family Physician |
| 2023 Canadian Thoracic Society Guideline on Pharmacotherapy in Patients With Stable COPD. | 2023 | Chest |
| GOLD 2023 Update: Implications for Clinical Practice. | 2023 | International Journal of Chronic Obstructive Pulmonary Disease |
| Position paper of the French Society of Respiratory Diseases regarding pharmacological treatment optimization for stable COPD in 2021. | 2022 | Respiratory Medicine and Research |
| LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations. | 2022 | Journal of Clinical Medicine |
| Update on guidelines for the treatment of COPD in Taiwan using evidence and GRADE system-based recommendations. | 2021 | Journal of the Formosan Medical Association |
| Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. | 2020 | American Journal of Respiratory and Critical Care Medicine |